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Tumor cells release extracellular microvesicles (MVs) in the microenvironment to deliver
biological signals to neighboring cells as well as to cells in distant tissues. Tumor-derived
MVs appear to play contradictory role promoting both immunosuppression and tumor
growth and both evoking tumor specific immune response. Recent evidences indicate
that tumor-derived MVs can positively impact Dendritic Cells (DCs) immunogenicity by
reprogramming DC antigen processing machinery and intracellular signaling pathways,
thus promoting anti-tumor response. DCs are considered pivot cells of the immune
system due to their exclusive ability to coordinate the innate and acquired immune
responses, cross-present exogenous antigens, and prime naïve T cells. DCs are
required for the induction and maintenance of long-lasting anti-tumor immunity and their
exploitation has been extensively investigated for the design of anti-tumor vaccines.
However, the clinical grade culture conditions that are required to generate DCs
for therapeutic use can strongly affect their functions. Here, we investigated the
immunomodulatory impact of MVs carrying the MUC1 tumor glycoantigen (MVsMUC1)
as immunogen formulation on clinical grade DCs grown in X-VIVO 15 (X-DCs).
Results indicated that X-DCs displayed reduced performance of the antigen processing
machinery in term of diminished phagocytosis and acidification of the phagosomal
compartment suggesting an altered immunogenicity of clinical grade DCs. Pulsing DCs
with MVsMUC1 restored phagosomal alkalinization, triggering ROS increase. This was not
observed when a soluble MUC1 protein was employed (rMUC1). Concurrently, MVsMUC1
internalization by X-DCs allowed MUC1 cross-processing. Most importantly, MVsMUC1
pulsed DCs activated IFNγ response mediated by MUC1 specific CD8+ T cells. These
results strongly support the employment of tumor-derived MVs as immunogen platforms
for the implementation of DC-based vaccines.
Keywords: dendritic cells, DC vaccine, microvesicles, cancer immunotherapy, antigen processing, phagosome,
tumor antigens, MUC1
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INTRODUCTION
Dendritic Cells (DCs) are antigen presenting cells (APCs) crucial
for the promotion and maintenance of the anti-tumor immune
response due to their ability to coordinate innate and adaptive
immune response and to activate T cells inducing immune
memory (1, 2). DCs are equipped with a variety of receptors able
to sense tissue and cellular damage; they are endowed with an
unique and powerful antigen processing machinery that enable
them to crossprocess and present antigens; lastly, they display
a complex pattern of costimulatory/inhibitory receptors/ligands
that regulate interactions with effector immune cells (3). These
biological features empower DCs to perform T cell cross priming
thus activating both CD4+ and CD8+ T cells (4, 5).
Indeed, the exploitation of DCs in order to activate, redirect
and boost the immune response against the tumor is one of
the first strategies foreseen for anti-cancer immunotherapeutic
purposes (6–8). Among the different biological and experimental
parameters that have to be considered in the design of DC-based
vaccines, antigen selection and modality of antigen loading are
key points that still require to be improved to obtain an optimal
DC vaccine (9). Optimization of immunogen formulation is also
crucial to compensate those biological changes that characterized
DCs grown in clinical grade culture conditions and that could
affect the overall immunostimulatory ability of DCs (10, 11).
Recently, cell-derived extracellular microvesicles (MVs) have
been regarded as an interesting option for the formulation of
DC-based vaccines.
Release of MVs is an inter-cellular communication
modality that allows the delivery of molecular signals into
the microenvironment triggering metabolic reprogramming of
the acceptor cells even in distant tissue districts, overcoming
cell-to-cell contact (12, 13). Distinct MV subsets are shed by each
cell and are heterogeneous for biogenesis, size, and molecular
cargo components (14).
During tumor transformation, MVs released by the
transforming cells exert apparently contradictory effects on
host immune response. Tumor MVs have been show to promote
tumor growth, modulate matrix components and trigger
immunosuppression thus leading to invasion and metastasis
(15–17). On the other hand, it is clear that tumor MVs can
activate and promote long lasting anti-tumor immune responses
(18–20). In mouse models tumor-derived MVs have been shown
to be optimal immunogens for immunotherapeutic vaccination
both in prophylactic and therapeutic settings (21). In addition,
the immunogenity of tumor MVs appeared to be superior to
the one of soluble antigens since they trigger a more efficient
anti-tumor immune response than soluble antigens (22). Recent
evidences suggest that immunogenicity of tumor-derived MVs
observed in vivo may be also dependent by the antigenic and
molecular signals that tumor MVs convey to DCs. Tumor-
derived MVs are source of tumor antigen repertoire and have
been shown to reprogram DC antigen processing and signaling
pathways, resulting in increased DC immunogenicity (23–26).
In this work, we investigated whether MV based immune
formulations could restore the biological performance of DCs
differentiated in X-VIVO 15 serum free medium (X-DCs).
Results indicated that X-DCs displayed a reduced performance
of the antigen processing machinery as compared to standard
DCs (S-DCs) i.e. reduced phagocytosis and acidification of the
phagosomal compartment.
The antigen processing ability of both X-DCs and S-DCs was
evaluated employing two distinct formulations of the MUC1
tumor glycoantigen: a soluble recombinant MUC1 glycoprotein
(rMUC1) and tumor-derived MVs carrying MUC1 (MVsMUC1),
isolated from the MUC1 transfected DG75 cell line (27). Results
indicated that only MVsMUC1 up-take restored the phagosomal
alkalinization of X-DCs and this event was dependent by the
modulation of the phagosomal radical oxigen species. Moreover,
MUC1 cross-processing to HLA class I compartment was still
occurring in X-DCs upon MV pulsing and IFNγ response
mediated by MUC1 specific CD8+T cells could be triggered
by MVsMUC1 pulsed DCs. These results strongly suggest that
the employment of MVs as immunogens for DC-based vaccine
may contribute to restore the functionality of antigen processing
machinery in clinical grade DCs, besides transferring the entire
antigenic repertoire of tumor cells. Also, these evidences support
further exploitation ofMVs based formulation as off the shelf/cell
free-immunogens for the implementation of DC-based vaccines.
MATERIALS AND METHODS
Recombinant MUC1 Glycoprotein (rMUC1)
rMUC1 was produced by CHO-K1 cells (ATCC CRL-9618)
transfected with a MUC1-murine-IgG2a fusion cDNA construct
containing 16 MUC1 tandem repeats. The secreted MUC1-
IgG was highly sialylated due to the translational modifications
occurring in CHO-K1 cells. The rMUC1 glycoprotein was
purified from cell culture supernatant by anion exchange
chromatography after cleavage of the Fc portion by enterokinase
treatment (28).
Dendritic Cell Generation
Dendritic cells were generated as previously described (29).
Briefly, Peripheral Blood Mononuclear Cells (PBMCs) were
isolated from buffy coat of healthy donors, by Ficoll-Hypaque
gradient (Lympholite-H, Canada) (Policlinico Umberto I Ethics
Committee- Protocol nr. 4214/2016; written informed consent
was obtained from the subjects in accordance with Declaration
of Helsinki). CD14+ monocytes were isolated from PBMCs by
immunoselection kit (StemCell Technologies Inc., CA, USA)
and cultured with RPMI 1640 (Sigma-Aldrich, MO, USA)
complemented with 10% Fetal Bovine Serum (FBS; Euroclone,
Italy) (S-DCs) or in clinical grade X-VIVO 15 culture medium
(X-DCs) (Lonza, Switzerland) in the presence of 500 UI/mL of
GM-CSF and 2,000 UI/mL of IL-4 (R&D Systems, USA) (day
0 and 2). Immature DCs (iDCs) grown in X-VIVO 15 were
indicated as X-DCs, while iDCs grown in the presence of FBS
were indicated as S-DCs. Cells were maintained in a humidified
atmosphere at 37◦C and 5% CO2 (HERAcell 150, AHSI, Italy).
At day 5, iDCs were matured (mDCs) by adding rhIL-1β (1,000
UI/mL−10 ng/mL), IL-6 (1,000 UI/mL−10 ng/mL), TNF-α (465
UI/mL−10 ng/mL) and prostaglandin E2 (1µg/mL) (all from
R&D Systems, USA) for 16 h.
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mDCs grown in the presence of RPMI+ 10% FBS or X-VIVO
15 were employed only for CD8+T cells activation and ELISpot
assay. Immature X-DCs and S-DCs were employed for all the
other experiments.
Cell Lines
DG75 cell line and MUC1-DG75–transfected cells were cultured
as previously described in RPMI+ 10% FBS (Euroclone) without
or with neomycin (1 mg/mL; Invitrogen, CA, USA), respectively
(27). Before MVs production, MUC1-DG75 cells were analyzed
for the expression of MUC1 by flow cytometry (see below).
Flow Cytometry
DC phenotype staining was performed using the following
antibodies directly conjugated with fluorescein isothiocyanate
(FITC) or phycoerythrin (PE): IgG1-FITC and IgG1-PE as
isotype controls (both from Biolegend); anti-HLAII-DR-FITC,
anti-CD86-FITC, anti-CD83-PE (all from BD Biosciences),
anti-CD40-PE, anti-CD14-PE, and anti-CCR7-FITC (all from
Biolegend). DCs (2 × 105 cells/50µL sample) were incubated
with conjugated MoAb (according to the manufacturer’s
recommendation) for 30min at room temperature (RT). After
washing (in 2mL of PBS w/o Mg++ and Ca++, centrifuged at
250 × g for 5min), cell pellet was resuspended in PBS (100 µL);
at least 1 × 104 events were evaluated using a FACSCanto II
flow cytometer running FACSDiva data acquisition and analysis
software (Becton Dickinson).
To evaluate MUC1 expressed by MUC1-DG75 cells, 1 ×
105 cells were incubated with MoAb Ma552 (1:40; Monosan,
Netherlands, 50 µL/sample) for 30min at RT and binding
revealed with FITC-conjugated anti-mouse antibody (1:600;
Jackson-Immunoresearch Laboratories, PA, USA). MoAb
MOPC21 (1:100; Sigma-Aldrich, 50 µL/sample) was employed
as isotype control.
MV Purification
MVs were purified from cell culture supernatant of MUC1-DG75
(MVsMUC1) or DG75 cells (MVsDG75) (23). To generate MVs,
cells were cultured 3.5 × 105 cells/mL in RPMI 1640 (Sigma-
Aldrich) complemented with 2% FBS (Euroclone) for 48 h.
Supernatant (70 mL/tube) underwent to serial centrifugation
steps at 4◦C (250 × g for 10min, 550 × g for 30min, 1,500
× g for 30min) (Allegra
TM
6R Centrifuges, Beckman Coulter,
USA). Then supernatant was ultracentrifuged at 10,000 × g for
30min at 4◦C. Following transfer in fresh tube, the supernatant
was ultracentrifuged at 100,000× g for 1 h at 4◦C (Type 35 rotor,
Beckman Coulter, USA). Following the last ultracentrifugation
step, supernatant was discarded and the final pellet containing
MVs was gently resuspended in PBS w/o Mg++ and Ca++ (100
µL/pellet), aliquoted and stored at−20◦C. Protein concentration
was measured by Bradford assay (Bio-Rad Laboratories, USA).
An average of 0. 95 µg/µL of MVsMUC1 and 0.91 µg/µL of
MVsDG75 was obtained.
MV Characterization
Size determination of MVsMUC1 was performed by Nanoparticle
Tracking Analysis (NTA) technology (30). MVs were thawed on
ice and diluted in PBS between 1:500 and 1:20,000 to achieve
the optimal number of MVs/mL. Three videos (30 s each) were
recorded for each sample loading, employing the NanoSight
NS300 instrument (Malvern Instruments Ltd, Malvern, UK).
Measurements were performed employing the NTA 2.3 analytical
software. Results were shown as the average of the three
recordings.
MUC1 expression on MVsMUC1 was evaluated by flow
cytometry. MVsMUC1 (5 µg/sample) were incubated with
the anti-MUC1 MoAb Ma552 (Monosan) (1:100 for 30min,
50 µL/sample, RT). After washing in PBS w/o Mg++ and
Ca++(1 mL/sample, 30min at 13,000 rpm, RT), MVsMUC1
were incubated with FITC-conjugated anti-mouse antibody
(1:600; Jackson-Immunoresearch Laboratories, 50 µL/sample).
MoAbMOPC21 (1:100; Sigma-Aldrich) was employed as isotype
control. To exclude background noise, flow cytometry analysis
was performed setting the lowest Forward Scatter Threshold
[300] and the highest FSC/SSC voltage. A total of 30,000
events were acquired with low flow rate, using a FACSCanto II
flow cytometer running FACSDiva data acquisition and analysis
software (Becton Dickinson).
Western Blot
MVsDG75, MVsMUC1 and extract of DG75-MUC1 cell line
(obtained by freeze and thaw method) (30 µg for sample) were
separated on 4–12% SDS-PAGE (95V, 220mA for 90min at RT)
and blotted onto nitrocellulose transfer membrane (Schleicher
und Schuell, DE). Prestained protein ladder (10 µL) by Nippon
Genetics Europe GmbH was used. After blocking (5% BSA
in PBS), membranes were incubated with anti-MUC1 MoAb
Ma552 (1:100, 1 h at RT; Monosan), followed by anti-mouse
Fc peroxidase-conjugated antibody (1:20,000; 1 h at RT;Jackson
ImmunoResearch, USA). Protein bands were detected with
enhanced chemiluminescence reagents (ECL Western Blotting
Detection; Amersham Biosciences, UK).
Measurement of DC Phagosomal pH
DC phagosomal pH was measured as previously described (23).
Briefly, immature DCs were pulsed (106 cells/100 µL) for 30min
at 37◦C in CO2-indipendent medium (Gibco-Life Technologies,
UK) with 3µm microbeads (Polysciences Inc., USA) coupled
with FITC (1 mg/mL) (pH sensitive, Sigma-Aldrich) and
FluoProbes 647 (1 mg/mL) (pH insensitive, Interchim, France).
After extensive washing in cold PBS w/o Mg++ and Ca++to
remove not internalizedmicrobeads, cells were incubated at 37◦C
(“chase”) at different time points (10, 20, 30, 60, and 120min)
in CO2-indipendent medium and immediately analyzed by
flow cytometry (FACSCanto II, FACSDiva software, Becton
Dickinson). A FL1(FITC)/FL4(FluoProbes 647) gate selective for
cells that had phagocytosed only one microbead was employed.
Values of the ratio between the Mean Fluorescence Intensity
(MFI) of FL1(FITC)/FL4(FluoProbes 647) were compared with
a standard curve obtained by suspending DCs that had
phagocytosed beads, in CO2-independent medium at a fixed pH
(ranging from pH 5.5 to pH 8) containing 0.1% Triton X-100
(Bio-Rad Laboratories, Inc., Italy).
The effect of MUC1 based immunogens on phagosomal pH
of X-DCs was analyzed by pulsing the immature X-DC samples
(106 cells/100 µL) for 30min at 37◦C in CO2-indipendent
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medium (Gibco-Life Technologies) with rMUC1 glycoprotein
(20µg/mL) and MVsMUC1 (500µg/mL). Then, the DCs samples
were processed as above described. To block NADPH oxidase
2 (NOX2) activity, 10µM Diphenyleneiodonium chloride (DPI,
Sigma-Aldrich) was added to DCs 30min before MVs pulsing
and it was maintained throughout the experiment in each
solution the DCs were suspended in.
Phagocytosis Assay
To evaluate phagocytosis capability, DCs (106 cells/100 µL) were
pulsed with 3µm microbeads (Polysciences Inc., USA) coupled
with FluoProbes 647 (ROS insensitive, Interchim) for 30min at
37◦C in the growth medium. The samples were then extensively
washed in cold PBS to remove not internalized microbeads. The
cells were resuspended in growth medium (106 cells/100 µL)
and kept at 37◦C for 1 h. After washing in cold PBS, samples
were analyzed (at least 2 × 105 events) by flow cytometry
employing FACScanto II (Becton Dickinson). As control, cells
were also kept at 4◦C on wet ice to block phagocytosis capability.
Phagocytosis was indicated as the percentage of fluorescence
positive cells subtracted of the fluorescence signal associated to
the corresponding control sample.
Immunofluorescence Microscopy
iDCs (both S-DCs and X-DCs) (106 cells/100µL) were incubated
with rMUC1 glycoprotein (20 µg) or MVsMUC1 (500µg/mL) in
growth medium for 2 h or 12 h at 37◦C, 5% CO2. At the end of
incubation, iDCs were washed twice in PBS and were cytospun
(8 × 104 cells/sample) and fixed with cold acetone/methanol
(1:1; Carlo Erba Reagents, Italy). iDCs were incubated in humid
chamber with the anti-MUC1MoAbMa552 (1:20, Monosan) for
45min at RT, washed in PBS (5min in orbital shaker, 3 times),
followed by FITC-conjugated goat anti-mouse F(ab)2 for 30min
at RT (1:100). Both dilutions were performed in PBS. MUC1
positive cells were counted (30 fields) for each experimental
condition and percentage was expressed as ratio between positive
and total cell in the field. Three independent experiments were
evaluated.
To study MUC1 cross-processing, the iDCs (both S-DCs
and X-DCs) (106 cells/100 µL) were incubated with rMUC1 or
MVsMUC1 for 12 h as above described. iDCs were then washed
and stained for MUC1 expression as above. After PBS rinse
(3 times, 5min, orbital shaker), block of aspecific sites was
performed by 15min incubation with Superblock reagent (50 µL
sample/slide). Following removal of the blocking solution, the
iDCs were then incubated with MoAbs anti-HLAII-DR (L243
clone, 100 µL of neat supernatant) or rabbit polyclonal antibody
anti-calreticulin (1:50; Stressgene, USA) (45min, RT in the dark)
to visualizedHLA class II and I compartments, respectively. After
washing (PBS, 3 times, 5min, orbital shaker), samples were then
incubated with Texas red–conjugated goat anti-mouse or anti-
rabbit antibody, respectively (1:200, 30min in the dark; Jackson
ImmunoResearch, USA).
Fluorescence signals were visualized with an Axiovert 200
inverted microscope (Zeiss, Germany); cells were scanned in a
series of 0.5µm sequential sections with an ApoTome System
(Zeiss) and images were all acquired by the digital camera
Axio CAM MRm (Zeiss). Image analysis was performed by
the Axiovision software (Zeiss) and a reconstruction of a
selection of three central optical sections was shown in each
figure. Quantitative analysis of the extent of colocalization of
fluorescence signals was performed using the Axiovision software
(Zeiss). The mean ± SE percent of colocalization was calculated
analyzing a minimum of 30 cells for each treatment randomly
taken from three independent experiments.
MUC1+ CD8+ T Cell Enrichment and IFNγ
ELISpot
MUC1+ CD8+ T cell enrichment and IFNγ ELISpot were
performed as previously described (23). Briefly, PBMCs of a
MUC1 vaccinated ovarian cancer patient (open-label phase
I/II safety clinical peptide vaccination trial (31), approved
by Policlinico Umberto I Ethics Committee and Italian
National Institute of Health/protocol no. LITRM/DIMIGE05/01;
Ethical Committee Protocol nr. 1454/2008) were isolated by
Ficoll/Hypaque density gradient. Written informed consent was
obtained from the subjects in accordance with Declaration
of Helsinki. CD8+ T cells were purified by CD8+ positive
immunoselection kit (Stemcell Technologies, USA) and kept in
RPMI + 5% FBS at 37◦, 5% CO2. The CD8
− cell fraction (4
× 106 cell/mL) was incubated overnight (o/n) with 50µg/mL
of MUC1159−167 peptide (SAPDNRPAL) (ClinAlfa, Switzerland)
and 5µg/mL β2-microglobulin (Sigma Aldrich) in RPMI + 1%
FBS, at 37◦, 5% CO2. The MUC1159−167 peptide specifically
binds HLAI-A2 groove (31). The following day, CD8− cells were
irradiated (30Gy) and plated with autologous CD8+ T cells (1:1;
2 × 106 total cells/mL) in RPMI + 5% FBS, supplemented with
IL-2 (50 UI/mL, Peprotech, USA) and IL-7 (1,000 UI/mL; R&D
System).
After 7 day of co-culture, freshly isolated and MUC1-
pulsed autologous PBMCs (generated as above described) were
irradiated and added to the culture (1:1), with IL-2 (50 UI/mL,
Peprotech, USA) and IL-7 (1,000 UI/mL; R&D System). At
the same time, autologous CD14+ cells were immunoselected
(Stemcell Technologies, USA) and cultured in RPMI + 10% FBS
or X-VIVO 15 in the presence of GM-CSF (500 UI/mL) and IL-4
(2,000 UI/mL) (day 0 and 2). At day 5, iDCs (1 × 105 cells/100
µL) were pulsed o/n with MVsMUC1 (500µg/mL), MVsDG75
(500µg/mL) or [MUC1159−167 peptide with β2-microglobulin]
(50 and 5µg/mL, respectively). After 2 h pulsing, the DC
samples were matured with cytokine cocktail, o/n. Following
maturation, mDCs were washed in PBS and added to MUC1+
enriched CD8+ T cells (1:5, respectively), previously expanded
in culture and purified by immunoselection to remove cell
debris. Pulsed mDCs/T cells were plated (1 × 105 T cells/2
× 104 DCs/200 µL /well) in duplicate onto the anti-IFNγ-
precoated (1:200; BD Biosciences) ELISpot plate (MultiScreen,
Merck, Germany), o/n. Unpulsed DCs + T cells were also
plated at the same concentration. IFNγ cytokine release was
detected with biotinylated anti-IFNγ antibody (1:250, 2 h; BD
Biosciences), revealed with streptavidin-alkaline phosphatase
(BD Biosciences) (1:1,000, 100 µL /well, 1 h) and chromogen
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substrate (SIGMA FAST BCIP/NBT, Sigma). Spots were counted
using the ImmunoSpot Image Analyzer (Aelvis, Germany).
The average values of the experimental conditions [(DCs
+ MUC1159−167) + CD8
+T cells] and [(DCs + MVsMUC1)
+ CD8+T cells] were subtracted of the average values of the
background samples [unpulsed DCs + CD8+T cells] and [(DC
+MVsDG75)+ CD8
+T cells], respectively.
Statistical Analysis
Statistics was performed using GraphPad Prism software, version
6 (GraphPad Software, Inc., USA). Results were expressed as
mean values ± SD. p-values were calculated using Student’s
t-test when comparing two groups of continuous variables.
Significance level was defined as p-value <0.05 (∗p < 0.05;
∗∗p < 0.01; ∗∗∗p < 0.005).
RESULTS
Dendritic Cells for Clinical Use Display a
Less Efficient Antigen Processing
Phagosomal Machinery
Serum-free culture conditions employed for generating DCs
for anti-tumor vaccination can alter DC phenotype, modifying
to some extent their immunogenicity (8, 10, 32). Indeed,
DCs grown in the serum free X-VIVO 15 medium (X-DCs)
acquired a spindle-like morphology, quite distinct from the one
observed in DCs grown in RPMI in the presence of FBS (S-
DCs) (Figures 1Ab,a respectively). Results from the phenotypic
analysis performed by flow cytometry, showed that at the
immature stage, X-DCs expressed significant higher levels of
the maturative marker CCR7 chemokine receptor (p < 0.05)
(Figure 1B). CD14 expression was slightly higher although not
significant in immature X-DCs, while no significant change in
the expression of other markers was observed between the two
DC cultures.
Following maturation, in both DC cultures the activation
markers were upregulated, although with a different intensity.
Mature X-DCs displayed a reduced expression of CD40
costimulatory molecule (p < 0.05) as compared to mature S-
DCs, as well as a trend in the reduction of CD86 and CD83
costimulatory molecules could be observed. These changes were
accompanied by the significant increase of CD14 in mature X-
DCs vs. mature S-DCs (p < 0.05). Again a trend in a more
pronounced expression of CCR7 marker was still maintained in
mature X-DCs (Figure 1B).
Phagocytosis is a crucial biological function of immature DCs
and it is a key step for the antigen loading of DCs for cancer
vaccines. Phagocytic activity of both immature S-DCs and X-DCs
was evaluated by flow cytometry, following the uptake of 3µm
microbeads, conjugated with FluoProbes 647, fluorochrome
not affected by changes in pH. After 1 h incubation at 37◦C,
phagocytosis of X-DCs was significantly reduced as compared
to S-DCs (p < 0.01) (Figure 1C). Phagosomal activity in DCs is
specifically dependent on a mild alkalinization, differently from
what is observed in other antigen presenting cells (APCs) such as
macrophages.
Kinetic of phagosomal pH in both immature X-DCs and S-
DCs was followed by flow cytometry. As shown in Figure 1D,
S-DCs presented a neutral phagosomal pH (7.01 pH) that
significantly increased after 2 h chase (7.35 pH) (p < 0.05).
X-DCs differently behaved: phagosomal pH of X-DCs was
significantly lower than S-DCs both at 10min and 120min chase
(p < 0.001). Furthermore, in X-DCs phagosomal pH appeared to
decrease during the chase, although not significantly.
These results suggest that clinical grade DCs have a phenotype
and a biological behavior that appears to remain at a more
immature stage with a more acid phagosomal compartment as
compared to standard S-DCs. This feature could contribute to
reduce antigen cross-processing efficiency of clinical grade DCs.
DC Uptake of the Tumor Associated MUC1
Antigen Carried by MVs Increases Antigen
Internalization and Induces Phagosomal
Alkalinization
We have recently shown that MV up-take by DCs allows cross-
presentation of the MUC1 tumor glycoantigen by triggering a
faster alkalinization of DC phagosomal compartment (23). We
therefore evaluated whether MV uptake could similarly impact
phagosomal pH in the clinical grade X-DCs.
MVs were isolated from the supernatant of MUC1-DG75
cell line (MVsMUC1). MV size characterization by Nanoparticles
Tracking Analysis (NTA) indicated that MVsMUC1 were
heterogeneous for size: 3 main vesicle populations could be
identified with a size corresponding to 105, 175, and 285 nm
(Figure 2A). The MUC1 tumor glycoantigen was a molecular
cargo component of the MVsMUC1 as characterized by flow
cytometry (Figure 2B) and Western blot analysis confirmed
the presence of the MUC1 antigen (Figure 2C). A soluble
recombinant form of MUC1 glycoprotein (rMUC1) was also
employed. The rMUC1 had a glycosylation profile (high level
of sialylation), similar to the MUC1 carried by MVsMUC1 as
defined by pattern reactivity ofMoAbs specific for distinctMUC1
glycoforms (27).
To evaluate whether phagosomal compartment was
differentially modulated by the up-take of the two distinct
MUC1 immunogens, X-DCs were pulsed with MVsMUC1
and the soluble rMUC1 glycoprotein for 30min (37◦C) and
then with FITC/FP647-coupled beads and pH kinetic was
followed for 2 h. Results indicated that MVsMUC1 significantly
increased the phagosomal pH of X-DCs within the first 60min
(reaching 7.05 pH at 20min) as compared to unpulsed X-DCs
(p < 0.05), then decreasing and reaching the same values
of unpulsed X-DCs at the end of chase. Uptake of soluble
rMUC1 glycoprotein did not modify the acidic phagosomal
microenvironment of X-iDCs (Figure 3A). To investigate
whether the phagosomal pH increase observed in clinical
grade X-DCs after MVs up-take was accompanied also by
modulation of ROS molecules, MVs-uptake effects were studied
in X-DC pretreated with DPI as shown in Figure 3B. DPI
treatment of X-DCs significantly decreased phagosomal pH
of X-DCs during the chase (p < 0.05). When DPI treated
X-DCs were pulsed with MVsMUC1 ([X-DCs + DPI] +
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FIGURE 1 | Clinical grade DCs display different biological features compared to standard S-DCs. (A) Morphological differences of DCs grown in RPMI + 10%FBS
(S-DCs) and in X-VIVO 15 (X-DCs) (a,b, respectively) visualized by phase contrast inverted microscope (ZEISS West Germany IM35, 3,2X). (B) Flow cytometry analysis
of immature and mature DCs (iDCs and mDCs, respectively) grown in FBS-RPMI or X-VIVO 15 after 6 day culture in the presence of GM-CSF, IL-4. iDCs were
matured with IL-6, IL-1β, PGE-2, and TNF-α on day 5. IgG1 PE and FITC were used as isotype controls and employed to evaluate fluorescence signal background
and set the gate. Results were shown as value of Mean Fluorescence Intensity (MFI) of each phenotypic marker subtracted of the corresponded negative control MFI
value and depicted as scatter plot (black circle for S-DCs; black triangles for X-DCs). Statistically significant differences between S-DCs vs X-DCs were indicated
(*p < 0.05). (C) Phagocytosis of S-DCs and X-DCs was evaluated at 1 h from the internalization of 3µm FITC/FluoProbes 647 coupled beads by flow cytometry
(FACSCanto II, FACSDiva software, BD Biosciences). Results were plotted as percentage of positive cells of experimental samples subtracted of the percentage of
positive cells of corresponding cell samples kept at 4◦C for 1 h (black circle for S-DCs; black triangles for X-DCs). (D) Phagosomal pH of clinical grade X-DCs (three
donor, black triangles), is compared to the S-DCs (five donors, black circles) at 10min and 120min of chase. Average of the results of each experiment is plotted as
black line. Dashed line indicates the pH neutrality value (pH 7). Significance between samples was evaluated by Student’s t test. (*p < 0.05; **p < 0.01, *** p < 0.005).
MVsMUC1) the phagosomal pH significantly increased in the
first 60min of chase (p < 0.05), although remaining lower
than untreated X-DCs. These results indicated that up-take
of MVsMUC1 also modulated antigen processing machinery
of X-DCs by inducing alkalinization of the phagosomal
microenvironment. The antigenic transfer of MUC1 was also
investigated evaluating the percentage of MUC1 positive DCs
following incubation with both MVsMUC1 and both rMUC1 by
immunofluorescence studies, at 2 h and 12 h of incubation at
37◦C (Figure 3C).
At 2 h pulsing, the percentage of X-DCs that had internalized
MVsMUC1 was lower than the corresponding S-DCs (p < 0.05).
A similar trend in decrease was also observed when the soluble
rMUC1 was employed as immunogen. At 12 h of pulsing this
difference was enhanced: the percentage of MUC1 positive X-
DCs was much lower than MUC1 positive S-DCs for both
MVsMUC1 and rMUC1 glycoprotein (p < 0.01 and p < 0.005,
respectively). Interestingly, MUC1 antigenic transfer to X-DCs
appeared to be more efficient when mediated by MVsMUC1
than the rMUC1 at 12h (p < 0.01). These results suggest
that MVsMUC1 may be more efficient in antigenic transfer
than the soluble rMUC1 glycoprotein, despite the fact that the
intracellular availability of the MUC1 antigen is strongly reduced
in X-DCs as compared to S-DCs.
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FIGURE 2 | Characterization of tumor-derived microvesicles (MVsMUC1). (A) Size measurement of MVs shed by the MUC1-transfected DG75 lymphoblastoid cell line
(MVsMUC1) using Nanosight NS300 that employs Nanoparticles Tracking Analysis (NTA) technology. Results are plotted as graph; y-axis: concentration of particles;
x-axis: size of particles in nanometer. The black curve is obtained by the merge of three independent measurements for each MV sample. (B) MUC1 expression in
MVsMUC1 by flow cytometry. MoAb MOPC21 was employed as isotype control (left). MUC1 expression was detected employing the MoAb Ma552 (right). (C)Western
Blot analysis to detect MUC1 in MVsDG75, MVsMUC1 and MUC1-DG75 cell extracts (30 µg/sample) employing the MoAb Ma552. The extract of MUC1-DG75 cell line
was used as positive control.
Tumor-Derived MVs Mediate MUC1
Antigen Cross-Processing in Clinical
Grade DCs and Activation of MUC1
Specific CD8+ T Cells
Clinical grade DCs seems to show some “macrophages-like”
features such as acid phagosomal pH and high ROS content in
their phagosomal compartment (data not shown). We wanted to
investigate further if this could affect their ability to cross-process
tumor associated antigens (TAA). Both X-DCs and S-DCs were
pulsed with MVsMUC1 and the rMUC1 soluble glycoprotein and
intracellular distribution of the MUC1 antigen was observed by
immunofluorescence, after 12 h.
In S-DCs pulsed with MVsMUC1 (Figure 4A, row 1 and
2), MUC1 colocalized with calreticulin, marker of HLA
class I compartment (38%) (Figure 4A, row 1), while
scarce colocalization with HLA-DR, marker of HLA class
II compartment (5%) was found (Figure 4A, row 2). When
rMUC1 was employed to pulse S-DCs, low colocalization
for both calreticulin and HLAII-DR compartment markers
was found (<18%) (Figure 4B, row 1 and 2). These results
confirmed previous observations indicating that only MUC1
supplied to DCs as cargo of MVs were routed to calreticulin+
compartment (27).
In X-DCs, following up-take of both immunogens, MUC1
colocalization was increased HLAII-DR positive compartment
Frontiers in Immunology | www.frontiersin.org 7 November 2018 | Volume 9 | Article 2481
Dionisi et al. Tumor MVs for DC Vaccines
FIGURE 3 | Tumor-derived MVsMUC1 efficiently increase X-DC phagosomal pH and transfer MUC1 antigen to X-DCs. (A) Kinetic of phagosomal pH (10–120min
chase) of X-DCs, pulsed with soluble rMUC1 or with MVsMUC1. Following MVsMUC1 uptake, phagosomal pH of X-DCs (light gray dashed line) was significantly
increased in the first 60min of chase (p < 0.05) as compared to unpulsed X-DCs (black continuous line). Soluble rMUC1 protein uptake did not alter phagosomal pH
of X-DCs (dark gray dashed line). The average ± SD of three independent experiments (3 different donors) was shown. *p < 0.05. (B) Phagosomal pH measurement
in X-DCs in the presence of 10µM Diphenyleneiodonium chloride (DPI), NOX2 inhibitor, without or with MVsMUC1. DPI treatment decreased pH compared to
untreated X-DCs (light gray dashed line vs. black continuous line, respectively). In [DPI-treated X-DCs + MVsMUC1] (black dotted line) phagosomal pH was partially
restored. The difference between [DPI treated X-DCs] and [DPI-treated X-DCs + MVsMUC1] was significant for the first 60min of chase (p < 0.05). Values are mean ±
SD of three independent experiments. *p < 0.05; **p < 0.01, ***p < 0.005. (C) MUC1 expression in DCs following pulsing with rMUC1 glycoprotein or MVsMUC1.
S-DCs (first row) and X-DCs grown in X-VIVO 15 (second row) were visualized by immunofluorescence staining after 2 and 12 h incubation, employing the anti-MUC1
MoAb Ma552 (green). The average ± SD of percentage of positive cells (evaluated by counting 30 fields for each experimental condition, three independent
experiments) was shown as histograms (White: S-DCs; gray: X-DCs). Uptake by X-DCs was significantly decreased as compared to S-DCs. Within the X-DCs,
MVsMUC1 uptake was higher than the soluble rMUC1 (p < 0.01). *p < 0.05; **p < 0.01, ***p < 0.005.
as compared to S-DCs (p < 0.01 for MVsMUC1 and p < 0.05
for rMUC1). In particular, MUC1 colocalized with HLAII-DR
molecules in dots, close to the plasma membrane in X-DCs
pulsed with MVsMUC1 (Figure 4A, row 4) as well as rMUC1
(Figure 4B, row 4). Interestingly, in X-DCs, colocalization of
MUC1 with calreticulin positive compartment was observed only
when X-DCs were pulsed with MVsMUC1, although at a lower
extent of the corresponding S-DCs (p < 0.05). rMUC1 did not
appear to colocalize significantly with calreticulin marker in
X-DCs.
These results showed that while the soluble rMUC1 was
mainly found in association with HLAII-DR, MVsMUC1 could
be up-taken and cross-processed in HLA class I and II
compartments by clinical grade X-DCs, although this was
reduced compared to S-DCs.
To investigate whether the reduced cross-processing of
MVsMUC1 in X-DCs was still sufficient to activate MUC1 specific
T cell responses, CD8+ T cells were isolated by immunomagnetic
selection from PBMCs of an ovarian cancer patient, previously
vaccinated with the HLAI-A2 restricted MUC1159−167 peptide
(31). MUC1 specific CD8+ T cells were expanded in vitro by a
two round stimulation with autologous PBMCs pulsed with the
MUC1159−167 peptide.
At the end of the culture, T cell activation was evaluated as
IFNγ release in ELISpot assay (Figure 4C). The MUC1 enriched
CD8+ T cells were stimulated by autologous X-DCs or S-
DCs, loaded with immunogenic MUC1159−167 peptide or pulsed
with MVsMUC1. T cells stimulated by unpulsed DCs or DCs
pulsed with MVsDG75 (MVs from untransfected DG75 cells)
were employed as background controls (for MUC1 peptide
loaded and MVsMUC1 pulsed DCs, respectively). As shown in
Figure 4C, X-DCs were less efficient as stimulator of IFNγ T-cell
mediated response, independently by the MUC1 immunogen
employed. MVsMUC1 appeared to perform better as immunogen
than the exogenous MUC1159−167 peptide. In particular in [X-
DCs+ MVsMUC1] induced a similar T response to [S-DCs +
MUC1159−167], suggesting that the MUC1 carried by MVs could
be processed and cross-presented to T cells also by X-DCs, whose
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FIGURE 4 | Clinical Grade DCs maintain the ability to cross-process antigen, when MUC1 is carried by MVs and to activate MUC1 specific CD8+ T cells. Intracellular
localization of MUC1 carried by MVsMUC1 (A) or as soluble rMUC1 glycoform (B) in S-DCs (first and second row) and in X-DCs (third and fourth row) were visualized
by immunofluorescence staining after 12 h of internalization employing the anti-MUC1 MoAb Ma552 (green) combined with antibodies specific for distinct intracellular
compartment markers (red). In particular: anti-calreticulin polyclonal rabbit antibody, [calreticulin ER resident protein, employed as marker for HLA class I
compartment] (first and third rows) and anti-HLAII-DR for HLA-II compartment (second and fourth rows). The percentage of colocalization (yellow) was calculated
(Continued)
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FIGURE 4 | analyzing a minimum of 30 cells for each treatment randomly taken from three independent experiments. Results are expressed as mean values ± SE in
histograms. Magnification, x63; Bar, 10mm. **p < 0.01 and *p < 0.05 for X-DCs vs. the corresponding S-DCs pulsed with MVsMUC1 or rMUC1. (C) ELISpot assay to
evaluate the IFNγ production by enriched MUC1-specific CD8+ T cells obtained from an ovarian cancer patient in response to mature S-DCs (left) or X-DCs (right)
loaded with MUC1159−167 peptide (white histogram) or pulsed with MVsMUC1 (grey histogram). The average values of the experimental samples [(DCs +
MUC1159−167) + CD8
+T cells] and [(DC + MVsMUC1 ) + CD8
+T cells] were subtracted of the corresponding background samples i.e., [unpulsed DCs + CD8+T
cells] and [(DCs + MVsDG75) + CD8
+T cells], respectively. Results were expressed as mean values ± SD of duplicates.
processing and presentation abilities were dampened by culture
conditions.
DISCUSSION
One of the critical key point in designing DCs-based antitumor
vaccines is the choice of antigen formulation: the ideal
immunogen should deliver a broad repertoire of TAAs combined
to activatory signals in order to potentiate immunostimulatory
capability of DCs. This strategy would reduce the possibility of
immune escape and overcome HLA haplotype restriction that is
a real limit for the peptide based DCs approach (33).
There is a compelling need to search for optimal immunogen
formulations to efficaciously target and load DCs with antigens,
and at the same time to activate them for improving anti-
tumor DCs performance. Nowadays, that immune checkpoint
blockade allows to clinically reverse the immune exhaustion,
DC-based vaccines are being reassessed as a powerful approach
to activate/maintain the unleashed antitumor memory T cell
responses in order to control tumor disease progression
(9, 34).
Cell released MVs display biological characteristics that
make them as optimal candidate as immunogen platform
able to simultaneously deliver multiple tumor antigens and
immunostimulatory signals to DCs (35). Tumor-derived MVs
can enhance the immunogenicity of soluble antigen (21, 22) and
induce CD8+ T-cell responses in in vitro human studies toward
tumor antigens (36). Delivery of the tumor antigens by MVs
also modulate cross-presentation of those tumor glycosylated
antigens such as MUC1 that are thought to induce only a
tolerogenic CD4+ T cell response, although being relevant for
tumor targeting (27). Furthermore, tumor-derived MVs have
been shown to activate DCs in vivo by delivering tumor DNA
triggering intracellular signaling cGAS/STING pathway resulting
in potent anti-tumor responses (24–26).
In this study, we provide evidences that clinical grade
culture conditions hamper DC immunogenicity by reducing
phagocytosis and inducing a macrophage like feature of the
phagosomal compartment i.e., strong acidification, besides
altering DCs phenotype. We showed that tumor-derived
MVs carrying the MUC1 tumor glycoantigen employed as
immunogen, restored phagosomal pH close to neutrality,
allowing cross-presentation of the tumor associated MUC1
glycoantigen and the activation of MUC1 specific CD8+ T cell
response.
Culture conditions are critical for DC differentiation process
from progenitor cells. It has described that ex-vivo DCs
for clinical use are less immunogenic, because of a reduced
expression of HLA and costimulatory molecules. Addition of
human serum (autologous or pooled) to implement clinical
grade DC performance appears to hamper cytokine production
and reduce migratory capacity of DCs (37, 38). Indeed, the
high plasticity of DCs, that enable them to quickly sense
in vivo stimuli, can become a critical point in formulating
experimental protocols for ex-vivo DC cultures (8). DCs
generated in X-VIVO 15 serum free medium (X-DCs) displayed
a spindle-like morphology and a distinct ability to respond to
maturative pro-inflammatory cytokines than S-DCs (DCs grown
in RPMI+10%FBS). Previous work had shown that DCs culture
in X-VIVO 15 performed poorly in phenotype and cytokine
secretion (10). Despite optimization of the culture protocol
(anticipating cytokine re-addition during the culture; Napoletano
C, unpublished), X-DCs still performed differently compare
to S-DCs. Immature X-DCs had increased expression of the
maturative CCR7 marker, while following maturation, CD14
marker was still maintained (p < 0.05). Also mature X-DCs
showed a lower upregulation of costimulatory molecules than
S-DCs.
This phenotype is associated to a reduced phagocytosis of
immature X-DCs that usually is a functional feature of the
mature DCs. This aspect can be quite relevant for the up-
take of immunogens that are based on protein or particulated-
based antigens. Most interestingly, the phagosomal machinery
appeared to be modified by clinical grade culture conditions.
X-DCs displayed a significant acidification of the phagosomal
compartment that was maintained during the time following
3µm beads phagocytosis, while phagosomal pH of S-DCs was
close to neutrality and increased during the incubation time
following 3µm bead internalization.
Phagosome is a crucial compartment for the ability of DCs
to cross-present antigens: it is considered a central hub for
the cell where molecular cargos are docked and then sorted to
other intracellular compartments of the cell (39). The cross-
processing ability of DCs is finely tuned by a mild alkalinization
of the phagosomal compartment. Induction of CD8+ T cells
was obtained only by priming with monocyte-derived DCs
with alkaline phagosomal pH, while macrophages, with an acid
phagosomal pH, did not cross-process antigen (40). In mouse
models, CD8+ DCswith a higher cross-processing ability showed
an alkaline phagosomal pH (41). It has been hypothesized
that alkaline pH delays protein degradation thus increasing the
antigen amount available for cytoplasmic transportation and
HLA-I association (39, 42, 43).
The results obtained suggest that X-DCs possess phagosomal
machinery with strong similarities to macrophages, that quickly
degrades the antigen thus favoring HLAII presentation and
the induction of CD4+ T cells. Thus, the reduced ability to
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internalize the antigen combined to the increased efficiency in
antigen degradation would imply a reduced immunogenicity of
the DC vaccine designed. To investigate if this was the case,
we employed two MUC1 based immunogens forms: a soluble
rMUC1 glycoprotein, produced in CHO-K1 cells and MVsMUC1,
tumor-derived MVs carrying the MUC1 antigen purified from
a MUC1 stable transfected cell line. Size characterization by
NTA indicated that vesicles were heterogenous and biochemical
characterization of cell markers (data not shown) indicated that
the prevalence of MVsMUC1 derived from plasma membrane
exocytic pathways. Indeed, after 12 h pulsing, X-DCs showed a
striking significant reduction of intracellular MUC1 distribution
than S-DCs, for both the immunogens employed (MVsMUC1:
p < 0.01; rMUC1: p < 0.005), strongly suggesting that the
reduced up-take and the acidic compartment of X-DCs hasten
degradation of MUC1 antigen.
We have recently shown that uptake of tumor-derived MVs
exerts an immunostimulatory effect on antigen presentation
by DCs, inducing a faster alkalinization of phagosomal
compartment thus allowing cross-presentation of the MUC1
tumor glycosylated antigen (23). This mechanism could be of
great relevance for shaping the immunogenicity of glycosylated
tumor antigens.
We then asked whether, tumor-derived MVs could be a
suitable immunogen formulation to counteract the phagosomal
alkalinization and restore a pH value close to neutrality.
Uptake of MVsMUC1 by X-DCs significantly restored the
phagosomal pH of X-DCs to neutrality in the first 60min
chase. This metabolic event is also supported by the observation
that following pulsing of X-DCs with MVsMUC1, intracellular
MUC1 distribution is significantly higher (p < 0.01) than X-DCs
pulsed with rMUC1, thus suggesting that protein degradation has
been lessened. Phagosomal pH is strictly dependent by Radical
Oxigen Species (ROS) level produced in the phagosome by
the combined and dynamically regulated function of NADPH
oxidase 2 (NOX2) and VATPase (41, 44).
Indeed, MVsMUC1 uptake contributes to phagosomal ROS
increase, as shown by NOX2 blocking experiments with the DPI
inhibitor. However, other metabolic pathways triggered by MV
uptake could be involved in the fine tuning of phagosomal ROS
balance and pH regulation.
Most important, MVsMUC1 internalization allowed MUC1
cross-processing by X-DCs, despite these cells displayed a
“macrophage-like” phagosomal compartment. After 12 h from
MV internalization, in X-DCs MUC1 colocalized with HLA class
II compartment (39%), but also with the calreticulin marker
employed as HLA class I compartment (21%). In S-DCs MUC1
colocalization was prevalent with the calreticulin+ compartment
(38%), as expected. The rMUC1 soluble glycoprotein was sorted
exclusively in HLAII compartment both in S-DCs and in X-
DCs. In DCs, cross-processing of soluble antigens occurs by
distinct mechanisms: the “cytosolic” and “vacuolar” pathways. In
the former, the internalized antigen sorted into the phagosome,
then translocates in the cytosol where proteasome degradation
occurs and proteolitic peptides are loaded by TAP dependent
mechanism in the ER where the association to MHCI occurs. In
the vacuolar pathway, exogenous antigens are degraded in the
endosome, loading endosome resident MHCI molecules (39, 45).
The co-localization of MUC1 with the ER marker calreticulin,
and the detection of MUC1 in the cytosolic fraction of MVsMUC1
pulsed DCs previously shown (27), clearly suggested that the
cytosolic pathway was involved in the MUC1 cross-processing
mediated by MVs delivery, although the vacuolar pathway
could not be excluded. These intracellular events resulted in
cross-presentation of theMUC1 antigen since X-DCs pulsed with
MVsMUC1 were able to activate CD8
+ T cells specific for the
HLA-A2 restricted MUC1159−167 epitope, although with a lower
efficiency than S-DCs, as expected.
Thus, delivery of antigenic cargo through MVs appeared to be
a possible strategy to empower antigen presenting ability of DCs
for clinical use.
Tumor-derived MVs immunogenicity could be possibly
enhanced by mean of genetic and biochemical interventions
with the ultimate goal to generate an off the shelf/cell free
immunogen (46, 47). Induced genome instability of tumor cells
could increase the amount of novel neoantigens that elicit
strong immune response (48), thus increasing the antigenic
cargo of the released MVs. Also, modulation of glycosylation
is an appealing option to harness MVs immunogenicity (49).
So far, glycosylation is regarded as a complex and finely
tuned signaling code among cells and microenvironment,
not just a “default cell décor” (50). DCs are endowed of
specific receptor, C-type lectin, recognizing selectively the
distinct glycan moieties (51). By specific and selective ligand
receptor interaction, glycan repertoire shapes immunogenicity
of the antigens by modulating their internalization and at the
same time triggering activatory/inhibitory signals to the DCs
(52–54). Selective genome editing strategies allow to control
glycan synthesis, thus obtaining cells (and therefore MVs)
with the desired glycan profile and defined immunoregulatory
properties (55).
In summary, we have investigated the immunomodulatory
impact of tumor-derived MVs carrying MUC1 as immunogen
in clinical grade culture condition DCs. Results indicate that
optimization of the MUC1 antigen cross-processing could be
induced upon tumor derivedMVsMUC1 internalization in clinical
grade X-DCs, despite their acidic phagosomal compartment,
that is a feature of macrophage cells. This effect appears to
be dependent by metabolic changes triggered by phagosomal
ROS increase and alkalinization. Furthermore, MVsMUC1 pulsed
DCs could stimulate MUC1 specific CD8+ T cells to produce
IFNγ response. We believe these results to further support the
exploitation of tumor-derived MVs as optimal immunogens for
DC-based anti-cancer vaccine.
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